Stage I Cross-Over Award Winner: Candace Floyd


Relief from chronic pain is of immediate and paramount importance to a large percentage of patients with SCI. We previously reported that the non-psychoactive cannabinoid cannabidiol (CBD) significantly decreases neuropathic pain associated with chemotherapeutic drug treatment in mice, and this effect requires activation of 5-HT1A serotonin receptors. Notably, CBD is a safe, non-toxic, neuroprotective compound with pleotropic effects that ultimately reduce oxidative stress and inflammation, suggesting it may also reduce reactive oxygen species formation and inflammatory signaling that lead to neuropathic pain after SCI. Moreover, mounting evidence supports a critical role for serotonergic signaling in modulating neuropathic pain. However, the effects of CBD on the development of post-SCI neuropathic pain are unknown. Thus, we propose to test the hypothesis that post-SCI administration of CBD reduces the development of neuropathic pain in a clinically relevant rat model of cervical contusion.

Back to Stage I Winners